Researchers analyzed genetic variation in 75,607 23andMe customers of European descent who self-reported being diagnosed or treated for depression and compared that to 231,747 “healthy controls” also of European descent. Comparing these analyses to a prior genome-wide study and a replication of this study, researchers found 17 genetic variations linked to depression at 15 locations on the genome.
“We hope these findings help people understand that depression is a brain disease, with its own biology,” said Roy Perlis, MD, of Boston-based Massachusetts General Hospital and an author involved in the study. “Now comes the hard work of using these new insights to try to develop better treatments.”
This study is significant for multiple reasons, reports The Washington Post. It is the first time researchers have discovered locations on the genome linked to depression in individuals of European ancestry. Second, the data came from individuals using a consumer-facing product and permitted 23andMe to use their information for research.
More articles on genomics:
Viewpoint: Privatized data contributes to health inequities, slow scientific progress
Watson’s data capabilities to help VA personalize cancer care for 10,000 veterans
Mayo Clinic, Transplant Genomics to develop diagnostic tests for organ donors
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
